• 1
    Estey E. Treatment of relapsed and refractory acute myeloid leukemia. Leukemia. 2000; 14: 476479.
  • 2
    Leopold LH,Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma. 2002; 43: 17151727.
  • 3
    Ravandi F,Kantarjian H,Giles F,Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004; 100: 441454.
  • 4
    Montgomery JA,Shortnacy-Fowler AT,Clayton SD, et al. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. J Med Chem. 1992; 35: 397401.
  • 5
    Parker WB,Shaddix SC,Chang CH, et al. effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991; 51: 23862394.
  • 6
    Carson DA,Wasson DB,Esparza LM, et al. Oral antilymphycyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro-2′ deoxyadenosine. Proc Natl Acad Sci U S A. 1992; 89: 29702974.
  • 7
    Xie KC,Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-β-D-arabinofuranosyl)adenine. Cancer Res. 1996; 56: 30303037.
  • 8
    Parker WB,Allan PW,Hassan AE, et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther. 2003; 10: 2329.
  • 9
    Waud WR,Schmid SM,Montgomery JA, et al. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids. 2000; 19: 447460.
  • 10
    Kantarjian H,Gandhi V,Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003; 21: 11671173.
  • 11
    Jeha S,Gaynon PS,Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006; 24: 19171923.
  • 12
    Kantarjian H,Gandhi V,Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003; 102: 23792386.
  • 13
    Faderl S,Gandhi V,O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005; 105: 940947.
  • 14
    Faderl S,Verstovsek S,Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006; 108: 4551.
  • 15
    Gandhi V,Estey E,Keating MJ,Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10( suppl 1): 109114.
  • 16
    Cooper T,Ayres M,Nowak B,Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005; 55: 361368.
  • 17
    Burnett AK,Baccarani M,Johnson P, et al. Clofarabine as first-line treatment of elderly (=65 yrs) AML patients with an unfavorable cytogenetic profile who are unsuitable for standard treatment. Haematologica. 2006; 91( suppl 1): 45.
  • 18
    Faderl S,Ravandi F,Ferrajoli A, et al. Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥60 years with newly diagnosed acute myeloid leukemia (AML). Blood. 2005; 106: 786a.
  • 19
    Agura ED,Berryman R,Cooper B, et al. Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. J Clin Oncol. 2007; 25: 372s.
  • 20
    Szmigielska-Kaplon A,Ciesielska E,Szmiegiero L,Robak T. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol. 2002; 68: 370375.